


Syngene

Putting Science to Work

Small Molecule Development & Manufacturing



Chemical Development



Highlights

- 125+ fume hoods in multiple suites
- Automated lab scale jacketed reactors (-70- to 180 °C)
- Flow Chemistry
- Dedicated process engineering and safety lab
- HPAPI development from lab to Manufacturing scale
- Therapeutic and Diagnostic Oligonucleotide- from Lab to Manufacturing scale
- Performance and Speciality Materials - synthetic organic chemistry, polymer chemistry and scale-up activities
- Integrated analytical services- analytical method development, validation, transfer and reference standard qualification
- Regulatory Support

Process Engineering and Scaleup

Capabilities

- Design of experiments (DoE)
- Quality by design (QbD)
- Reaction Kinetics studies
- Process Modelling and Simulation
- Reaction Optimization studies
- Unit operation and processes
 - Filtration, Distillation, Extraction, Drying, Corrosion studies etc
- Process crystallization studies
- Advanced PAT tools for Process understanding (FBRM, PVM, React-IR etc)
- Flow Chemistry development
- Mass & Energy Balances
- Technology absorption and transfer

Process Safety Management

Capabilities

- Process Safety studies (DSC, RC1e, ARC, Vent Sizing etc)
- Powder safety studies (Fall Hammer test, MIE, MIT, Ignition test, MEC, LOC etc)
- Process Safety Information
- Process risk assessment (What-if, HAZOP, PHIRA, FMEA, Qualitative and Quantitative risk assessments etc)
- Pre-startup safety reviews
- Asset Integrity and reliability studies



Oligonucleotides

Salient Features

Process Development

- Natural & Modified | siRNA | ASOs | Anti-microRNA | Aptamer | CpG
- Conjugated oligos | Molecular beacons | Fluorescent oligos | Probes & Primers
- Backbone modifications | Base modifications | Sugar modifications
- Synthesizer & Scale: ÄKTA oligopilot 100 | 250 μ mol - 6 mmol (100 mg - 5 g / batch (non-GMP))

Analytical Support

- Comprehensive analytical support | Method Development & Validation
- Combination of orthogonal techniques
- Impurity Analysis | Identification | Sequencing | Characterization
- Release specifications – General | Compendial | Oligo-specific methods
- Forced degradation | Informal stability | ICH stability

Manufacturing

- cGMP facility of 1500 sq. ft. | Fully qualified equipment and area
- Controlled environment to limit Endotoxin & Bioburden
- Located in a GMP certified/ USFDA inspected facility
- Synthesizer & Scale: ÄKTA oligopilot 400 | 4 mmol - 45 mmol (5 g - 135 g / batch (GMP/non-GMP))
- Support for regulatory filing | CMC documentation suitable for Phase 1/2 IND

Formulation

- Drug substance characterization and method development
- Formulation development and optimization
- Analytical methods development and pre-validation for the Drug Product
- Supportive stability study
- Component compatibility study and miscellaneous studies



High Potent API

Capabilities

- Integrated solutions from Discovery, Process R&D, Optimization, Scale-up & Clinical supplies to Commercialization
- OEL determination toxicity studies
- cGMP manufacturing
- Facilities designed to handle cytotoxic, cytostatic, and high potent compounds with OEL values in the range of $>100 \mu\text{g}/\text{m}^3$ to $0.01 \mu\text{g}/\text{m}^3$
- Isolators for full spectrum of unit operations from Sampling, Dispensing and Weighing, Reactor charging, Filtration, Drying, Milling & Sieving to Packing
- Broad range of Reactors (Stainless steel, Glass lined, Hastelloy)
- Dedicated facility for Prep-HPLC and lyophilization of HPAPI molecules
- Development and manufacturing of ADCs, including the linker development, optimization, and characterization

Highlights

- Highly experienced process chemists, analytical chemists, process engineers, manufacturing and QC team
- cGMP facility for lab-scale to commercial-scale manufacturing including registration and validation batches for regulated market
- Integrated with a separate cGMP facility to manufacture non potent compounds.
- Provision to add reactor & matching downstream equipment to enhance capacity/capability
- PAI inspection for the API registration and validation batches



Performance and Specialty Materials

Capabilities

- Synthesis and Purification of Monomers/Polymers
- Functionalization chemistry
- Material Characterization
- Process Development & Process Engineering
- GMP and Non-GMP manufacturing capabilities

Monomers

Acrylates; Schiff bases; Ionic liquids; Radical compounds; Macrocycles; Heterocycles, End functionalization of polymers; Light and air sensitive compounds

Polymers

Supramolecular Polymer; Conducting Polymers; Polymer Self Assembly; Self-healing Polymers; Hydrogels; Silicones; Random/Block/star/comb copolymers

Materials

Inorganic Materials; Additives; Catalysts; Biomaterials; Nanomaterials-Nanofibers, CarbonNanoTube (CNT)

Highlights

- Excellent track record of continuous supply of polymers & specialty materials (250-500 kg/batch), Nano materials (1-2 kg) and additives (10-100 kg scale)
- cGMP compliant facilities inspected by USFDA and audited by global customers and QPs from Europe
- Innovation on specialty materials and polymers from lab scale to commercial manufacturing level



Formulation Development

Capabilities

- Pre formulation profiling including salt and polymorph screening
- Preclinical formulation development
- Drug-drug and drug-excipient compatibility study
- Formulation development – oral solids, liquids, semisolids (OEL up to 1 µg/m³)
- Formulation development – injectables (OEL up to 0.1 µg/m³)
- Ready to use and lyophilized injectable product development, including nanosuspensions
- High potent injectable dosage form development
- Development of palatable dosage forms for companion animals (hard chews and soft chews), spot on formulations
- Formulation Development of oral solids (modified release, controlled released, timed release, delayed release)
- Novel drug delivery systems (liposomes, nano-emulsions, biodegradable polymers-based microspheres, nanoparticles and in situ depots)
- Enabling formulation approaches – spray-dried dispersion (SDD), hot melt extrusion (HME), lipid based, complexation-based self-micro emulsifying drug delivery system (SMEDDS) and nanosuspensions
- Analytical method development and validation
- CGMP manufacturing and clinical supplies
- Clinical supplies manufacturing for solid orals (OEL up to 1 µg/m³)
- Scale-up and technology transfer
- Phase I/phase II and phase III clinical supplies/registration batches / process validation batches
- Small scale commercial supply
 - Niche and orphan drug products (current batch size up to 120 kg batch size (upscaling up to 200-400 kg scale by 2023)

Integrated CMC Development Services – Lead to FIH

- Salt and fit for purpose polymorph screening for first- in- human (FIH) studies
- Pre-formulation package to assess the physico-chemical properties and design
- Identification of the right enabling approach by screening different enabling approaches using scientific rationale post drug developability assessment
- Advantage of multidisciplinary scientific team in the same campus
- Fit-for-purpose analytical method development and validation

Highlights

- Quick-to-clinic approaches for phase 1 clinical studies (FIH)
- Expertise in animal health care formulation development
- Expertise in parenteral formulation development and small-scale clinical batch manufacturing (ready-to-use vials and prefilled syringes)
- Delivered over 20 integrated CMC projects in last five years
- Can involve in 505(b)(2) programs as early as ideation process, repurposing of molecules and identifying unmet medical need
- Clean regulatory track record with different regulatory bodies across the globe (USFDA and Russian Regulatory Agency- approved, oral solid manufacturing facility)

Oral Solid Dosage Forms

Capabilities

- State-of-the-art GMP manufacturing facility for solid orals (phase 1 to low volume commercials)
- APIs having OEL up to $1 \mu\text{g}/\text{m}^3$ can be handled for drug product manufacturing
- Batch sizes of up to 120 kg can be handled currently, upgradable up to batch of 200-400 kg by 2023
- Unit operations such as dry and wet granulation, wurster coating, blending, spray drying, Tablet compression, tablet coating, encapsulation, extrusion and spheronization
- Automatic capsule filling machine for pellets, powders and mini tablets
- Blister packing machine; ALU- ALU, PVC-ALU, PVC/PVDC-ALU and automatic bottle packing machine for tablets and capsules

Highlights

- Expertise in enabling technologies (spray drying, hot melt extrusion, nanosuspension, SMEDDS) and modified release formulation development
- Successfully completed "ideation to PoC " for a hybrid application for EU/505(b)2 for U.S.
- Strong track record of consistently delivering integrated CMC programs year-on- year (18 projects over the past five years)
- Experienced in late-phase product development requirements and USFDA query responses
- US FDA and Russian Regulatory- approved manufacturing, quality control and stability facility
- Consistently delivering 35-40 GMP campaigns per year



Sterile Fill Finish Facility

Clinical supplies and small-scale manufacturing

Capability to manufacture ready-to-use solutions and lyophilized products (pre-sterilized vials and prefilled syringes)
OEL: $\geq 1 \mu\text{g} / \text{m}^3$ in GMP environment

- Aseptic filtration and filling
- Terminal sterilization
- Batch size of 500 to 25,000 vials, 5L- 50L
- Lyophilization capability for vials (3500 vials of 10R size)
- Capability to handle clinical batch manufacturing of small molecules and biologic products
- Storage chambers of 2 – 8°C and - 30°C

Equipment:

- Vials+ PFS combi filling line under isolator (Make: MAR Italy)
- Isolator-based robotic filling machine for vials and PFS
- Ready-to-use nested vials: Liquid and lyophilized vials with II volume of 0.5 ml to 50 ml (ISO 2R to ISO 30 R)
- Ready- to- use nested prefilled syringes: Fill volume of 0.1 ml to 10 ml
- Terminal sterilizer; jacket cooling available after sterilization cycle.
- Lyophilizer: Toon China (Model: Lyo-3), Grade B area

We are 21 CFR-compliant wherever applicable



Formulation Development for Animal Health

Supporting drug product development and clinical supply manufacturing for four out of top 10 Animal Health companies in the world

Capabilities

- Dedicated GMP facility for animal health products (up to OEL $1\mu\text{g}/\text{m}^3$)
- Pre formulation, formulation development and manufacture of oral solids chewable dosage forms for standalone or combination products
- Manufacturing and packing of conventional and bolus tablets
- Development of injectables, spot-on/pour-on formulations
- Development of palatable hard and soft chews tablets for API requiring masking of taste
- Blister packaging capability for small and bolus tablets; PVC-ALU, PVC-PVDC/ALU, Alu-Alu, & Aclar and bottle packaging
- Experienced team dedicated for analytical activities for animal health products

Highlights

- Drug product development, clinical batches, VICH stability studies for multi API combination multi-drug hard chew and soft chew tablets
- Manufacturing and packaging of clinical supplies for companion animals
- Drug product development and lab stability studies for topical and injectable dosage forms
- Robust analytical methods development and validation for combination products and stability studies



Analytical Development

- Method development
- Method verification/validation
- Structural characterization and elucidation
- Reference and working standards qualification
- Identification and characterization of impurities
- Prep HPLC/chiral purification
- Residual Solvent Analysis
- Elemental impurities analysis
- Impurity analysis
- Method transfer
- Stability studies
- Phys-Chem studies/5-batch analysis



Analytical capabilities for Drug Products



Tablets capsules:

Assay & content uniformity, related substances, water content, drug excipient compatibility studies, filter compatibility, solubility, degradation studies, antioxidant and preservatives, DT, dissolutions (release media, multimedia & bio-relevant media), PSD, pXRD and residual solvents.



Powder for Injection (lyophilized / dry powder, microspheres, liposomes):

Assay, related substances, residual solvents, reconstitution stability study, diluent/component stability compatibility, assay of encapsulated/free drug, polymer characterization, lipid characterization, assay of antioxidant/preservatives, dissolution, particle size distribution.



Suspensions, Solutions:

pH, viscosity, light transmission matter/color, Density (Wt/mL), solubility, AET, assay & CU, degradation studies, drug excipient compatibility studies, related substances, antioxidant and preservatives, dissolutions and PSD.



Suspensions (ophthalmic suspensions, vial suspension for injection):

Assay, related substances, residual solvents, component stability compatibility, assay antioxidant and preservatives, dissolution, particle size distribution, *In vitro* comparative nasogastric feeding tube studies for vial suspension.



Liquid Injections (ampoules, prefilled syringes, vials): Assay, related substances, residual solvents, diluent and component stability compatibility, particulate matter.



Semisolid dosage forms:

pH, viscosity, physical appearance, density (Wt/mL), AET, assay & CU, degradation studies, drug excipient compatibility studies, related substances antioxidant & preservatives, IVRT, texture analysis.

Analytical capabilities for complex injectables

Pre-formulation studies	Liposomal injection	Injectable nanosuspension	Extended release injectable microspheres
<ul style="list-style-type: none"> • API characterization • API solubility • Excipient's evaluation • pH solubility and impact on stability • Impact of various parameters on API stability • Aggregate evaluation 	<ul style="list-style-type: none"> • Assay; free/entrapped drug; other critical excipient • Related substances • Phospholipid content (lyso forms) • Size and zeta potential • Internal environment (volume, pH, and ionic concentration): • State of encapsulated drug • <i>In vitro</i> drug release dissolution method using USP Type IV • Lipid degradation 	<ul style="list-style-type: none"> • Dissolution method • Development – USP yype IV Assay • Related substances • Free fatty acid content • Phospholipid content • Drug partitioning • Globule size and zeta potential • Redispersibility 	<ul style="list-style-type: none"> • Dissolution method development using Incubator orbital shaker or bottle rotating • Assay of free drug and encapsulated drug • Particle morphology size, shape • Molecular weight determination by GPC for polymer • Related substances • Polymer degradation


Analytical capabilities for Drug Substances

One-stop solution for all Analytical needs: Small molecules, oligonucleotides & performance and specialty materials (PSM)

Solid state characterization	Structural characterization	Method development/ validation	Extraction and purification
<ul style="list-style-type: none"> • Optical microscopy • XRPD • DSC/ TGA • DVS • Particle size analyzer 	<ul style="list-style-type: none"> • NMR • LC/MS • LC/MS-MS • HRMS • GC/MS 	<ul style="list-style-type: none"> • HPLC, GC, IC • Quantitative NMR • Wet chemistry • LC/MS, GC/MS • Genotoxic impurity methods • Forced degradation studies 	<ul style="list-style-type: none"> • Semi prep HPLC • SFC • Column chromatography • Flash chromatography



Integrated Analytical support: Non-GMP and GMP activities




Non GMP Activities

- Phase-appropriate API, intermediate, DP analytical method development
- Support to chemists/process scientists / formulators for:
 - Route scouting, PRD activities
 - Tox/clinical formulation development
- Salt and polymorph screening
- Preformulation and excipient -- compatibility support
- Development stability of DS and DP (in use, accelerated, follow-up)
- Processing and packaging component compatibility

GMP Activities

- Phase-appropriate method qualification/ validation
- Release of RMs/ Intermediates/ DS/ excipients/ DPs
- DS and DP GMP stability
- Use time study for injectable DP



Stability services: Salient features

Our Study expertise

- Complete Product lifecycle studies: Early phase till commercial
- Developmental stability
- Follow-up stability
- Forced degradation
- Freeze-Thaw stability
- In-Use stability
- Photo stability
- Registration stability
- RLD stability
- Commercial stability
- Transport assessment studies

Formulation types we deal in

Drug substances, drug intermediates including HPAPIs

- Tablets
- Capsules
- Soft gels
- Injectables
- Creams
- Ointments
- Eye drops
- Parenterals
- Lotions
- Emulsions
- Gels
- Suspensions
- Patches
- Liquid Spray
- Aerosols
- Powders

Our State-of-the-art facilities

- Biometric chamber access
- Multi-client ICH stability facility with long-term and intermediate testing conditions
- Uniquely coded and appropriately labelled samples
- Chromatography data systems
- 24*7 Online Temp/RH monitoring with backup facility
- Data managed electronically with systems 21CFR, Part 11 compliant



Commercial Manufacturing

Capabilities

Manufacturing of Regulatory starting materials, APIs, HPAPI, NCEs & Novel advanced intermediates

Mfg. facility	nGMP	S1 Kilo Lab	Unit 2 Kilo Lab	HPAPI	S14	Mangalore
Range	160 L - 5000 L	10 L - 20 L	10 L - 50 L	60 L - 630 L	60 L - 8,000 L	2000 L - 12,500 L
Total Capacity	26,640 L	120 L	90 L	2010 L	63,600 L	69,600 L
Largest reactor	5,000 L	20 L	50 L	630 L	8,000 L	12,500 L
# Reactors	15	3	4	5	32	11
Total number of reactors (Manufacturing Volumes)					70 reactors (>161,000 L)	

Salient Features

- 24/7 operations to ensure optimal utilization of resources
- Broad range of Reactors (Stainless steel, Glass lined, Hastelloy)
- Broad range of Chemistries (Asymmetry catalysis, halogenation, etc.)
- High potency expertise (Cytotoxic, Cytostatic compounds up to 0.1 µg/m³ - 8h OEL)
- High vacuum (< 10 Torr) & high temperature (140°C) distillations
- Hydrogenator for highly acidic/basic reactions with capacity up to 4 KL and 26 bar pressure rating
- 12 KL cryogenic reactor operating within a temperature range of -90°C to 140°C
- Particle size reduction to < 10 microns with nitrogen and air in class 100,000 area
- Batch sizes range between 100kg (Bangalore) to 40 MT per annum (Mangalore)
- PMDA (commercial) and USFDA (RSM) approved Bangalore S14 manufacturing facilities



Syngene

Putting Science to Work

Clinical Development



Clinical Development

Capabilities

BA/BE Studies to Support Development of Generic Drugs

- Conducted over 600 BA/BE or PK/PD or Phase-1 trials [incl. FIH studies]
- Clinic with 190 ward care beds and 12 ICU beds
- Over 200+ validated methods available as per USFDA guidelines
- Total Mass Specs: 11 [API 4000s and API 6500s]
- State-of-the-art instrumentation [with qualification]
- Analysis of drug(S) and/or metabolite(s) in biological specimen [e.g. blood, plasma, serum, human aqueous humor etc.] to support TK< PK, early phase clinical development, BA/BE and TDM studies
- Team of 45 qualified and experienced researchers with experience in method development, validation and regulated Bioanalysis for a wide range of chemically diverse drug molecules

Clinical Trial Management (Phase I-III Trials) of Novel Drugs and Biosimilars

- One of the most experienced Indian CROs in conducting patient-based trials
- Over 100 clinical trials conducted for registering products in US, Europe, India and ROW countries
- Deep experience in Oncology, Diabetes and Auto-immune disorders
- Conducted multiple COVID-19 related trials in India
- Full service solutions, incl. Clinical Supplies Management, Central Lab and CDM & Biometrics

Central Laboratory Services Encompassing Clinical/ Safety Lab and Bioanalytical Services for Small Molecules & Biologics

- CAP accredited Central lab offering clinical testing services exclusively for Phase 1-IV clinical trials and BA/BE studies
- GLP-certified, FDA-inspected bioanalytical lab offering PK, ADA and Nab assays
- 21CFR-11 compliant laboratory information management system with customizable project management and reporting capabilities
- Supported over 100 NDAs/BLAs submitted to US FDA, EMA and PMDA
- r HbA1c

Regulated Bioanalytical Lab for Large Molecules

- 3 blockbuster MAbs approved by USFDA and EMA, based on the bioanalytical data submitted from this lab
- Experience with 7 Biosimilars, 22+ Monoclonal Antibodies and few vaccines
- 600,000+ samples imported (from various parts of the globe) and analysed till date, with a track record of Zero compromise on sample shipment
- Existing customers include 5 of the top 10 global Big Pharma/Biotech companies and 1 of the top Animal Health companies
- 15+ years of rich and diverse experience
- Adept at Method Transfer, Development and Validation based on FDA/EMA/WHO guidance
- Influenced favourable change in Indian Govt's policy on import of biological samples for testing – no wait period for license, ~4-6 days sample travel time from US/EU, no wait period for clearance from customs, expedited reporting can be handled, especially for Dose Escalation studies requiring 1 week TAT

Clinical Data Management and Biometrics

- Stand alone or integrated data management for Phase I-IV studies
- Statistics and SAS programming for Clinical and non-clinical development programs

Data Acquisition:

- Web based through in-house eCRF
- Paper CRF based data capture



Regulatory Track Record

- Audited by major life sciences Co's & Regulatory agencies from North America and Europe
- Certifications/ Accreditations: ISO 9001:2008, 14001, OHSAs 18001, AAALAC, GLP
- HPU & Bioanalytical labs are inspected by:
 - US-FDA – 9 audits
 - EMA – 3 audits
 - Thai FDA for GLP – 2 audits
 - ANVISA – Brazil – 3 audits
 - UK-MHRA – 1 audit
- Regulatory track record for Regulated Bioanalytical Lab for Large Molecules :
 - US-FDA – 1 audit
 - PMDA – 1 audit





Syngene
Putting Science to Work

About Syngene

Syngene Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com

© 2023 Syngene International Limited, All Rights Reserved.

Stay Connected 